Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cinzia Lanzi

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Biochemical Pharmacology|February 13, 2022
Combinatorial strategies to potentiate the efficacy of HDAC inhibitors in fusion-positive sarcomasCinzia Lanzi, Giuliana Cassinelli
Biochemical Pharmacology|June 12, 2020
Receptor tyrosine kinases and heparan sulfate proteoglycans: Interplay providing anticancer targeting strategies and new therapeutic opportunitiesCinzia Lanzi, Giuliana Cassinelli
Molecules (Basel, Switzerland)|November 11, 2018
Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal ActivityCinzia Lanzi, Giuliana Cassinelli
Advances in Experimental Medicine and Biology|April 11, 2020
Heparanase: A Potential Therapeutic Target in SarcomasGiuliana Cassinelli, Cinzia Lanzi
Current Medicinal Chemistry|February 21, 2017
Targeting Heparan Sulfate Proteoglycans and their Modifying Enzymes to Enhance Anticancer Chemotherapy Efficacy and Overcome Drug ResistanceCinzia Lanzi, Nadia Zaffaroni, Giuliana Cassinelli
Cancer Letters|September 27, 2016
The heparanase/heparan sulfate proteoglycan axis: A potential new therapeutic target in sarcomasGiuliana Cassinelli, Nadia Zaffaroni, Cinzia Lanzi
Frontiers in Oncology|September 19, 2022
Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression driversGiuliana Cassinelli, Sandro Pasquali, Cinzia Lanzi
Biochemical Pharmacology|November 26, 2008
Targeting RET for thyroid cancer therapyCinzia Lanzi, Giuliana Cassinelli, Valentina Nicolini, et al.
Biochemical Pharmacology|August 4, 2023
Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitorsCinzia Lanzi, Noemi Arrighetti, Sandro Pasquali, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|May 25, 2015
New mechanisms for old drugs: Insights into DNA-unrelated effects of platinum compounds and drug resistance determinantsLaura Gatti, Giuliana Cassinelli, Nadia Zaffaroni, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Biochemical Pharmacology|February 13, 2022
Combinatorial strategies to potentiate the efficacy of HDAC inhibitors in fusion-positive sarcomasCinzia Lanzi, Giuliana Cassinelli
Biochemical Pharmacology|June 12, 2020
Receptor tyrosine kinases and heparan sulfate proteoglycans: Interplay providing anticancer targeting strategies and new therapeutic opportunitiesCinzia Lanzi, Giuliana Cassinelli
Molecules (Basel, Switzerland)|November 11, 2018
Heparan Sulfate Mimetics in Cancer Therapy: The Challenge to Define Structural Determinants and the Relevance of Targets for Optimal ActivityCinzia Lanzi, Giuliana Cassinelli
Advances in Experimental Medicine and Biology|April 11, 2020
Heparanase: A Potential Therapeutic Target in SarcomasGiuliana Cassinelli, Cinzia Lanzi
Current Medicinal Chemistry|February 21, 2017
Targeting Heparan Sulfate Proteoglycans and their Modifying Enzymes to Enhance Anticancer Chemotherapy Efficacy and Overcome Drug ResistanceCinzia Lanzi, Nadia Zaffaroni, Giuliana Cassinelli
Cancer Letters|September 27, 2016
The heparanase/heparan sulfate proteoglycan axis: A potential new therapeutic target in sarcomasGiuliana Cassinelli, Nadia Zaffaroni, Cinzia Lanzi
Frontiers in Oncology|September 19, 2022
Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression driversGiuliana Cassinelli, Sandro Pasquali, Cinzia Lanzi
Biochemical Pharmacology|November 26, 2008
Targeting RET for thyroid cancer therapyCinzia Lanzi, Giuliana Cassinelli, Valentina Nicolini, et al.
Biochemical Pharmacology|August 4, 2023
Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitorsCinzia Lanzi, Noemi Arrighetti, Sandro Pasquali, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|May 25, 2015
New mechanisms for old drugs: Insights into DNA-unrelated effects of platinum compounds and drug resistance determinantsLaura Gatti, Giuliana Cassinelli, Nadia Zaffaroni, et al.
Pageof 5